What if drug discovery took months, not decades?
Drug discovery is slow, costly and often unsuccessful. DTR hears how GATC Health is applying AI and multiomics to make the process faster, more precise and less reliant on trial and error.
List view / Grid view
Drug discovery is slow, costly and often unsuccessful. DTR hears how GATC Health is applying AI and multiomics to make the process faster, more precise and less reliant on trial and error.
Discover the key scientific, strategic and manufacturing factors that could decide whether your bsAb succeeds in the clinic or stalls in development.
An interview with Thibault Géoui reveals why this technology wave might finally break through pharma's productivity crisis – and why it will take longer than the optimists claim.
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
Researchers at Florida A&M University have identified a new compound – NSL-YHJ-2-27 – that disrupts key survival pathways in aromatase inhibitor-resistant breast cancer cells – offering a potential new treatment for hard-to-treat cases.
Scientists in China have used 3D bioprinting to grow kidney tumours from patients’ own cells, creating realistic models that could speed up development of personalised treatments.
New research from Harvard Medical School shows that natural lithium deficiency in the brain may be a key early factor driving Alzheimer’s disease – which allow for the development of new approaches to preventing and reversing cognitive decline.
Stanford Medicine researchers have developed a targeted brain cell transplant that replaced most diseased microglia in mice with Sandhoff disease – extending their lifespan and reversing symptoms
Drug discovery company, TauGen, has filed a US patent application for a new series of drug candidates targeting endoplasmic reticulum (ER) stress – a key factor in secondary brain injury following traumatic brain injury (TBI).
12 August 2025 | By Wuxi Biologics
Struggling with low-affinity TCRs or poor yields? Learn scalable workflows to boost expression, improve binding and speed TCR-TCE discovery.
Oral peptide-based drugs are set to revolutionise the pharmaceutical industry, overcoming the long-standing challenge of poor bioavailability. Santosh Kulkarni reveals how new breakthroughs in drug discovery and delivery offer the potential for more convenient, effective treatments for a range of conditions – without the need for injections.
AI is moving beyond drug design to answer a critical question: can a promising compound actually be manufactured at scale? By predicting synthetic feasibility early, machine learning tools are helping drug developers avoid costly failures, streamline R&D and design molecules that are both effective and practical to produce.
Australian scientists have, for the first time, visualised a malaria parasite protein complex–a discovery that has led to a new mRNA vaccine capable of blocking the parasite’s reproduction in mosquitoes and potentially halting transmission.
Porosome Therapeutics have announced new advancements in Alzheimer’s treatment – presenting therapies that restore neuronal function, reduce Tau protein levels and reverse disease pathology in human brain organoids.
Johns Hopkins University scientists have engineered a new multi-region brain organoid that mimics early human brain development. The model offers a powerful new tool for studying disorders like autism, schizophrenia and Alzheimer’s disease.